| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 19, 2025The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire
-
Mar 24, 2022
TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:...
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Sep 22, 2021Medtronic Will Move to Request Litigation Proceedings Resume
Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed an additional...
-
Sep 13, 2021Medtronic Receives Affirmation of Three Additional Sacral Neuromodulation Patents
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral...
-
Feb 18, 2021
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of...
-
Sep 25, 2020U.S. Patent and Trademark Office Rejects IPR Challenge to Medtronic Patent
Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal...
-
Aug 5, 2020First Patient Receives New Sacral Neuromodulation Device Implant at Cleveland Clinic
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for...
-
Aug 3, 2020World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans
DUBLIN, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug...
-
Jan 13, 2020Full-Body MRI-Conditional InterStim II and InterStim Micro Systems Offer Lifestyle-Friendly Choices in Sacral Neuromodulation Therapy to Europeans Suffering from Incontinence
DUBLIN, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE Mark for its InterStim™ Micro neurostimulator and InterStim™ SureScan™ MRI leads —...
-
Nov 4, 2019Action Seeks Relief to Prevent Further Infringement of Medtronic Patents
DUBLIN, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Medtronic, Inc. (NYSE:MDT) today filed a lawsuit against Axonics Modulation Technologies, Inc. (“Axonics”) alleging infringement of patents related to...
-
Oct 7, 2019Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues
DUBLIN, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has filed a pre-market approval (PMA) supplement with the United States Food and Drug Administration (FDA) for...
-
Dec 17, 2018Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence
DUBLIN - December 17, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system,...
-
Jul 17, 2017The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder
DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...
-
Mar 30, 2016New Medtronic Treatment Targets Underlying Bladder and Brain Miscommunication and Could Bring Desperately Needed Relief to Tens of Millions Struggling with OAB
DUBLIN - March 30, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of its NURO(TM) System that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of overactive...
-
Oct 7, 2014FDA-Approved System Provides Patients with Added Benefits While Testing Innovative Therapy for Bladder and Bowel Incontinence
MINNEAPOLIS - October 7, 2014 - After living with overactive bladder and urinary retention symptoms for 11 years, Jennifer LaForest, a 26-year-old woman from Auburn Hills, Michigan, recently...
-
Jul 21, 2011Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall
MINNEAPOLIS, Jul 21, 2011 (BUSINESS WIRE) -- Twenty-five long-distance runners who benefit from medical technology will be honored as "Medtronic Global Heroes" when they run the Medtronic Twin...
-
May 24, 2011Record Fourth Quarter Revenue of $4.3 Billion Driven by Strong International Growth of 12%
MINNEAPOLIS, May 24, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 29, 2011. Medtronic recorded fiscal...
-
Apr 1, 2011Unique Sacral Nerve Stimulation Therapy Now Available for Treatment of Chronic Fecal Incontinence
MINNEAPOLIS, Apr 01, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim(R) Therapy for Bowel Control. InterStim...
-
Mar 3, 2011Consensus Paper Suggests Medtronic ITB Therapy is an Effective Treatment for Control of Severe Spasticity, a Frequent and Disabling Symptom of MS
MINNEAPOLIS, Feb 03, 2011 (BUSINESS WIRE) -- A new scientific article has been published demonstrating the profound impact of spasticity on patients with multiple sclerosis and the benefits and...
-
Feb 20, 2011Revenue of $4.0 Billion Grew 3% on Strength of New Products
MINNEAPOLIS, Feb 22, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2011, which ended January 28, 2011. The company...
-
Feb 4, 2011Consensus Paper Suggests Medtronic ITB Therapy is an Effective Treatment for Control of Severe Spasticity, a Frequent and Disabling Symptom of MS
MINNEAPOLIS, Feb 04, 2011 (BUSINESS WIRE) -- A new scientific article has been published demonstrating the profound impact of spasticity on patients with multiple sclerosis and the benefits and...
-
Nov 29, 2010International Revenue of $1.6 Billion Grew 6% on a Constant Currency Basis; 4% As Reported
MINNEAPOLIS, Nov 23, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2011, which ended October 29, 2010. The company...
-
Nov 4, 2010Educational Campaign Encourages Women to Seek Support for Bladder Control Issues
MINNEAPOLIS, Nov 04, 2010 (BUSINESS WIRE) -- In support of Bladder Health Awareness Month and the struggles 33 million Americans face year-round with bladder control issues, Medtronic, Inc. (NYSE:...
-
Nov 1, 2010
MINNEAPOLIS, Nov 18, 2010 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT), the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA)...